Publications

A selective list of recent publications

Select Publications (Current or past lab members are highlighted; Additional publications may be searched via PubMed)

  1. Archin N.M., Margolis D.M. Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis. 2014 Feb;27(1):29-35.
  2. Manson McManamy M.E., Hakre S., Verdin E.M., Margolis D.M. Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors. Antivir Chem Chemother. 2014 Jan 29;23(4):145-149.
  3. Barton K. and Margolis D. Selective targeting of the repressive transcription factors YY1 and cMyc to disrupt quiescent human immunodeficiency viruses. AIDS Res Hum Retroviruses 2013 Feb;29(2):289-298.
  4. Barton K.M., Burch B.D., Soriano-Sarabia N., Margolis D.M. Prospects for treatment of latent HIV. Clin Pharmacol Ther. 2013 Jan;93(1):46-56.
  5. Archin N.M.Liberty A.L., Kashuba A.D., Choudhary S.K., Kuruc J.D., Crooks A.M., Parker D.C., Anderson E.M., Kearney M.F., Strain M.C., Richman D.D., Hudgens M.G., Bosch R.J., Coffin J.M., Eron J.J., Hazuda D.J., Margolis D.M. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012 Jul 25;487(7408):482-5.
  6. Archin N.M., Vaidya N.K., Kuruc J.D., Liberty A.L., Wiegand A., Kearney M.F., Cohen M.S., Coffin J.M., Bosch R.J., Gay C.L., Eron J.J., Margolis D.M., Perelson A.S. Immediate antiviral therapy appears to restrict resting CD4+ T cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8.
  7. Choudhary S.K.Archin N.M.Cheema M.Dahl N.P., Garcia J.V., Margolis D.M. Latent HIV-1 infection of resting CD4+ T cells in the humanized Rag2-/-γc-/- mouse. J Virol. 2012 Jan;86(1):114-20.
  8. Archin N.M.Cheema M., Parker D., Wiegand A., Bosch R.J., Coffin J.M., Eron J., Cohen M. and Margolis D.M. Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 2010 Feb 23;5(2):e9390.
  9. Archin N.M.Keedy K.S., Espeseth A., Dang H., Hazuda D.J. and Margolis D.M. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS. 2009 Sep 10;23(14):1799-806.
  10. Levesque M.C., Moody M.A., Hwang K.K., Marshall D.J., Whitesides J.F., Amos J.D., Gurley T.C., Allgood S., Haynes B.B., Vandergrift N.A., Plonk S., Parker D.C., Cohen M.S., Tomaras G.D., Goepfert P.A., Shaw G.M., Schmitz J.E., Eron J.J., Shaheen N.J., Hicks C.B., Liao H.X., Markowitz M., Kelsoe G., Margolis D.M. and Haynes BF. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009 Jul 7;6(7):e1000107. Epub 2009 Jul 7.
  11. Choudhary S.K., Rezk N.L., Ince W.L., Cheema M., Zhang L., Su L., Swanstrom R., Kashuba A.D. and Margolis D.M. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. J Virol. 2009 Aug;83(16):8254-8. Epub 2009 Jun 3.
  12. Keedy K.S.Archin N.M., Gates A.T., Espeseth A., Hazuda D.J., Margolis D.M. A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression. J Virol. 2009 May;83(10):4749-56. Epub 2009 Mar 11.
  13. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science. 2009 Mar 6;323(5919):1304-7.
  14. Archin N.M., Espeseth A., Parker D., Cheema M., Hazuda D. and Margolis D.M. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. 2009 Feb;25(2):207-12.
  15. Vahey M.T., Wang Z., Su Z., Nau M.E., Krambrink A., Skiest D.J. and Margolis D.M. CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. AIDS Res Hum Retroviruses. 2008 Aug;24(8):1047-66.
  16. Archin N.M., Eron J.J., Palmer S., Hartmann-Duff A., Martinson J.A., Wiegand A., Bandarenko N., Schmitz J.L., Bosch R.J., Landay A.L., Coffin J.M. and Margolis D.M. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008 Jun 19;22(10):1131-5.
  17. Bowman M.C., Ballard T.E., Ackerson C.J., Feldheim D.L., Margolis D.M. and Melander C. Inhibition of HIV fusion with multivalent gold nanoparticles. J Am Chem Soc. 2008 Jun 4;130(22):6896-7. Epub 2008 May 13.
  18. Choudhary S.K., Archin N.M. and Margolis D.M. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis. 2008 Apr 15;197(8):1162-70.
  19. Jiang G., Espeseth A., Hazuda D.J. and Margolis D.M. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol. 2007 Oct;81(20):10914-23. Epub 2007 Aug 1.
  20. Margolis, D.M. and Archin, N.M. Eliminating persistent HIV infection: getting to the end of the rainbow. J Infect Dis. 2007 Jun 15;195(12):1734-6. Epub 2007 May 2.
  21. Skiest D.J., Su Z., Havlir D.V., Robertson K.R., Coombs R.W., Cain P., Peterson T., Krambrink A., Jahed N., McMahon D. and Margolis, D.M.; AIDS Clinical Trials Group 5170 Study Team. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis. 2007 May 15;195(10):1426-36. Epub 2007 Apr 6.
  22. Klichko, V., Kaur, R.J., Archin, N., Lehrman, G, and Margolis, D.M. Hexamethylbisacetamide remodels the Human Immunodeficiency Virus type 1 promoter and induces Tat-independent HIV-1 expression without cellular activation. J. Virology, 2006; 80:4570–4579